Skip to main content
Year archive

Spexis AG — 2018 filings

All 19 regulatory filings released by Spexis AG (SPEX) in 2018, sourced directly from the official regulator.

19 Filings
2018 Period
2018 filings (19)
Filing Released Lang
Polyphor announces positive results from the FDA Type B Guidance meeting on the planned Phase III study for balixafortide
Regulatory Filings
2018-12-03 English
Polyphor wins the Swiss Technology Award 2018
Regulatory Filings
2018-11-23 English
Balixafortide combination with eribulin in metastatic breast cancer data presented at ESMO 2018 show consistent positive trend for all efficacy endpoints, including overall survival
Regulatory Filings
2018-10-24 English
Polyphor announces protocol agreement with the FDA for the second pivotal Phase III study of murepavadin
Regulatory Filings
2018-10-24 English
CMDO Debra Barker to leave Polyphor; Frank Weber to assist in the transition
Board/Management Information
2018-10-24 English
Polyphor to present new survival data for balixafortide at the 2018 European Society for Medical Oncology (ESMO) Congress
Regulatory Filings
2018-10-18 English
Polyphor announces financial results for the first half 2018
Earnings Release H1 2018
2018-09-06 English
Novo Holdings invests CHF 6.8 Million in Polyphor to accelerate the development of novel antibiotics against multi-drug resistant Gram-negative pathogens
Share Issue/Capital Change
2018-09-06 English
Polyphor announces listing of new shares related to the convertible loan facility agreement with the Wellcome Trust
Share Issue/Capital Change
2018-07-17 English
Polyphor announces publication of positive proof of concept data for innovative immuno-oncology candidate balixafortide in The Lancet Oncology
Earnings Release Q2 2018
2018-04-30 English
Polyphor presents new data at ECCMID on murepavadin and on its novel class of OMPTA antibiotics targeting WHO priority 1 multi-drug resistant pathogens
Regulatory Filings
2018-04-24 English
U.S. FDA grants Fast Track designation for Polyphor's innovative immuno-oncology candidate balixafortide in combination with eribulin as third line therapy for metastatic breast cancer
Regulatory Filings
2018-04-19 English
Polyphor to present data at the 28th European Congress of Clinical Microbiology
Regulatory Filings
2018-04-16 English
Polyphor successfully completes Wellcome Trust collaboration for development of novel antibiotics against multi-drug resistant Gram-negative pathogens
Capital/Financing Update
2018-04-13 English
Polyphor announces enrollment of first patient in Phase III clinical trial for murepavadin
Legal Proceedings Report
2018-03-27 English
Polyphor presents positive proof of concept data for innovative immuno-oncology candidate balixafortide at European Breast Cancer Conference
Regulatory Filings
2018-03-23 English
Polyphor announces successful end of Phase I meeting with FDA on its innovative immuno-oncology candidate balixafortide
Regulatory Filings
2018-03-09 English
Polyphor AG: Polyphor enters worldwide exclusive license agreement with Santhera to develop and commercialize POL6014 in cystic fibrosis and other pulmonary diseases
Regulatory Filings
2018-02-15 English
Polyphor: Global No. 2 in the 2018 Biopharmaceuticals Antimicrobial Resistance Benchmark published by the Access to Medicine Foundation
Regulatory Filings
2018-01-23 English